CIP2A overexpression is associated with c-Myc expression in colorectal cancer

Cancer Biology and Therapy

Volumn 13, Issue 5, 2012, Pages 289-295

  Böckelman, Camilla ^a,b,c   Koskensalo, Selja ^c   Hagström, Jaana ^b   Lundin, Mikael ^a   Ristimäki, Ari ^a,b   Haglund, Caj ^b,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

c Myc; CIP2A; Colorectal cancer; Prognosis; Survival

Indexed keywords

MYC PROTEIN; ONCOPROTEIN; PROTEIN CIP2A; PROTEIN P53; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; COLORECTAL CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION;

EID: 84857887423     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.18922     Document Type: Article

References (24)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90; PMID:21296855; http://dx.doi. org/10.3322/caac.20107.
2. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2009; 18:1688-94; PMID:19505900; http://dx.doi.org/10.1158/1055-9965.EPI-09-0090.
3. Ferrari P, Jenab M, Norat T, Moskal A, Slimani N, Olsen A, et al. Lifetime and baseline alcohol intake and risk of colon and rectal cancers in the european prospective investigation into cancer and nutrition (EPIC). Int J Cancer 2007; 121:2065-72; PMID:17640039; http://dx.doi.org/10.1002/ijc.22966.
4. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319:525-32; PMID:2841597; http://dx.doi. org/10.1056/NEJM198809013190901.
5. Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut 2011; 60:116-29; PMID:20921207; http://dx.doi.org/10. 1136/gut.2009.206250.
6. Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Bottzauw T, et al. CIP2A inhibits PP2A in human malignancies. Cell 2007; 130:51-62; PMID:17632056; http://dx.doi.org/10.1016/j.cell.2007.04.044.
7. Li W, Ge Z, Liu C, Liu Z, Bjorkholm M, Jia J, et al. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence or differentiation of tumor cells. Clin Cancer Res 2008; 14:3722-8; PMID:18559589; http://dx.doi. org/10.1158/1078-0432.CCR-07- 4137.
8. Katz J, Jakymiw A, Ducksworth MK, Stewart CM, Bhattacharyya I, Cha S, et al. CIP2A expression and localization in oral carcinoma and dysplasia. Cancer Biol Ther 2010; 10:694-9; PMID:21068540; http://dx.doi.org/10.4161/cbt.10.7. 12895.
9. Vaarala MH, Vaisanen MR, Ristimäki A. CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res 2010; 29:136; PMID:20964854; http://dx.doi.org/10.1186/1756-9966-29-136.
10. Qu W, Li W, Wei L, Xing L, Wang X, Yu J. CIP2A is overexpressed in esophageal squamous cell carcinoma. Med Oncol 2010; In press; PMID:21140243; http://dx.doi.org/10.1007/s12032-010-9768-9.
11. Wang J, Li W, Li L, Yu X, Jia J, Chen C. CIP2A is overexpressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. Int J Lab Hematol 2011. 33:290-8; PMID:21219591; http://dx.doi.org/10.1111/j.1751-553X.2010.01288.x.
12. Khanna A, Böckelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, et al. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst 2009; 101:793-805; PMID:19470954; http://dx.doi.org/10.1093/ jnci/djp103.
13. Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ, et al. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol 2011; 18:857-65; PMID:20842459; http://dx.doi.org/10.1245/s10434- 010-1313-8.
14. Böckelman C, Hagström J, Mäkinen LK, Keski-Säntti H, Häyry V, Lundin J, et al. High CIP2A immuno-reactivity is an independent prognostic indicator in early-stage tongue cancer. Br J Cancer 2011; 104:1890-5; PMID:21610708; http://dx.doi.org/10.1038/ bjc.2011.167.
15. Böckelman C, Lassus H, Hemmes A, Leminen A, Westermarck J, Haglund C, et al. Prognostic role of CIP2A expression in serous ovarian cancer. Brit J Cancer 2011; 105:989-95; PMID:21897396; http://dx.doi.org/10.1038/bjc.2011.346.
16. Côme C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, et al. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 2009; 15:5092-100; PMID:19671842; http://dx.doi. org/10.1158/1078-0432.CCR-08-3283.
17. Wang WS, Chen PM, Chiou TJ, Liu JH, Lin JK, Lin TC, et al. Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma. Clin Cancer Res 2007; 13:3597-604; PMID:17575224; http://dx.doi. org/10.1158/1078-0432.CCR-06-2601.
18. ARF and cyclin D2 expression in primary colorectal carcinomas. Diagn Mol Pathol 2010; 19:194-200; PMID:21052002; http://dx.doi.org/10.1097/PDM.0b013e3181e202f2.
19. Grady WM, Markowitz SD. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet 2002; 3:101-28; PMID:12142355; http://dx.doi.org/10.1146/annurev.genom.3.022502.103043.
20. Khanna A, Okkeri J, Bilgen T, Tiirikka T, Vihinen M, Visakorpi T, et al. ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PLoS ONE 2011; 6:17979; PMID:21445343; http://dx.doi. org/10.1371/journal.pone.0017979.
21. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001; 159:2249-56; PMID:11733374; http://dx.doi. org/10.1016/S0002-9440(10)63075-1.
22. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4:844-7; PMID:9662379; http://dx.doi.org/10.1038/ nm0798-844.
23. Kallioniemi OP, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001; 10:657-62; PMID:11257096; http://dx.doi. org/10.1093/hmg/10.7.657.
24. Soo Hoo L, Zhang JY, Chan EK. Cloning and characterization of a novel 90 kDa 'companion' autoantigen of p62 overexpressed in cancer. Oncogene 2002; 21:5006-15; PMID:12118381; http://dx.doi. org/10.1038/sj.onc.1205625.